READ IAN C
Known title: DirectorCIK: 0001372915
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Viatris Wins FDA Approval for RYZUMVI and Advances Pacira Deal. Viatris secured U.S. FDA approval for RYZUMVI, a treatment for presbyopia, which is relevant to its partnership with Opus Genetics. The company is also moving forward with a deal involving Pacira, a development analysts are watching closely. These moves add to the company's pipeline and strategic direction.
Transaction History
| EMPD | ▲ Buy | Grant | 30,000 | $300K | 7/21/2025 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 166 | $0 | 3/21/2022 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 13,996 | $0 | 3/2/2022 | View on chart |
| VTRS | ▲ Buy | Option Exercise | 335 | $0 | 3/2/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
Empery Digital Faces ATG Capital Allegations and Proxy Vote
ATG Capital has accused Empery Digital of misleading statements and lack of accountability. ISS recommends a vote on ATG’s GOLD proxy card, adding pressure on shareholders. SeekingAlpha notes the stock trades near $0.60, far below its 52‑week low, and highlights an upcoming catalyst that could influence the price. These developments add uncertainty to the company’s outlook.
Empery Digital Faces ATG Capital Allegations and Proxy Vote. ATG Capital has accused Empery Digital of misleading statements and lack of accountability. ISS recommends a vote on ATG’s GOLD proxy card, adding pressure on shareholders. SeekingAlpha notes the stock trades near $0.60, far below its 52‑week low, and highlights an upcoming catalyst that could influence the price. These developments add uncertainty to the company’s outlook.